Immune-checkpoint inhibition for tumor prevention in a preclinical Lynch syndrome model
Preventive ICI prolongs overall survival of cancer-prone mice. The sustained immune modulation and normal bone marrow hematopoiesis may pre-sensitize late-onset dMMR tumors to a second round of immunotherapy. Hence, we highlight the importance of preventive strategies for germline MMR mutation carriers and recommend improved screening of patients eligible for prophylactic ICIs to improve long-term outcomes.
Authors
- Maja Hühns (ORCID: https://orcid.org/0000-0003-3911-8754)
- Caterina Redwanz (ORCID: https://orcid.org/0009-0005-7815-0994)
- Sonja Oehmcke-Hecht (ORCID: https://orcid.org/0000-0002-3368-6219)
- Annabell Wolff (ORCID: https://orcid.org/0009-0007-3348-8005)
- Claudia Maletzki (ORCID: https://orcid.org/0000-0002-8389-8439)
- Paula Krone
- Johanna Maennicke
- Wendy Bergmann‐Ewert (ORCID: https://orcid.org/0000-0001-7221-3900)
- Christian Junghanss
Institutions
- Universitätsmedizin Greifswald (DE)
- University of Rostock (DE)
Publication Details
- Journal
- Translational Oncology
- Published
- 2025-07-16
- DOI
- https://doi.org/10.1016/j.tranon.2025.102472
- Citations
- 1
- Primary Topic
- Genetic factors in colorectal cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.47